149 related articles for article (PubMed ID: 33863820)
1. Kinetic and Static Analysis of Poly-(Adenosine Diphosphate-Ribose) Polymerase-1-Targeted
Young AJ; Pantel AR; Viswanath V; Dominguez TL; Makvandi M; Lee H; Li S; Schubert EK; Pryma DA; Farwell MD; Mach RH; Simpkins F; Lin LL; Mankoff DA; Doot RK
J Nucl Med; 2022 Jan; 63(1):44-50. PubMed ID: 33863820
[TBL] [Abstract][Full Text] [Related]
2. [18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study.
Pantel AR; Gitto SB; Makvandi M; Kim H; Medvedv S; Weeks JK; Torigian DA; Hsieh CJ; Ferman B; Latif NA; Tanyi JL; Martin LP; Lanzo SM; Liu F; Cao Q; Mills GB; Doot RK; Mankoff DA; Mach RH; Lin LL; Simpkins F
Clin Cancer Res; 2023 Apr; 29(8):1515-1527. PubMed ID: 36441795
[TBL] [Abstract][Full Text] [Related]
3. The Development of
Lee HS; Schwarz SW; Schubert EK; Chen DL; Doot RK; Makvandi M; Lin LL; McDonald ES; Mankoff DA; Mach RH
Radiol Imaging Cancer; 2022 Jan; 4(1):e210070. PubMed ID: 35089089
[TBL] [Abstract][Full Text] [Related]
4. Molecular imaging of PARP in cancer: state-of-the-art.
Filippi L; Urso L; Frantellizzi V; Marzo K; Marzola MC; Schillaci O; Evangelista L
Expert Rev Mol Diagn; 2023; 23(12):1167-1174. PubMed ID: 38009232
[TBL] [Abstract][Full Text] [Related]
5. [(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.
Edmonds CE; Makvandi M; Lieberman BP; Xu K; Zeng C; Li S; Hou C; Lee H; Greenberg RA; Mankoff DA; Mach RH
Am J Nucl Med Mol Imaging; 2016; 6(1):94-101. PubMed ID: 27069769
[TBL] [Abstract][Full Text] [Related]
6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
7. In vivo visualization of PARP inhibitor pharmacodynamics.
McDonald ES; Pantel AR; Shah PD; Farwell MD; Clark AS; Doot RK; Pryma DA; Carlin SD
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33884961
[TBL] [Abstract][Full Text] [Related]
8. Preliminary evaluation of a novel
Zhou D; Xu J; Mpoy C; Chu W; Kim SH; Li H; Rogers BE; Katzenellenbogen JA
Nucl Med Biol; 2018 Nov; 66():26-31. PubMed ID: 30195072
[TBL] [Abstract][Full Text] [Related]
9. Tracer Kinetic Analysis of (S)-¹⁸F-THK5117 as a PET Tracer for Assessing Tau Pathology.
Jonasson M; Wall A; Chiotis K; Saint-Aubert L; Wilking H; Sprycha M; Borg B; Thibblin A; Eriksson J; Sörensen J; Antoni G; Nordberg A; Lubberink M
J Nucl Med; 2016 Apr; 57(4):574-81. PubMed ID: 26795290
[TBL] [Abstract][Full Text] [Related]
10. Simplified Methods for Quantification of
Jansen BHE; Yaqub M; Voortman J; Cysouw MCF; Windhorst AD; Schuit RC; Kramer GM; van den Eertwegh AJM; Schwarte LA; Hendrikse NH; Vis AN; van Moorselaar RJA; Hoekstra OS; Boellaard R; Oprea-Lager DE
J Nucl Med; 2019 Dec; 60(12):1730-1735. PubMed ID: 31000583
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic Evaluation of the Tau PET Radiotracer
Wooten DW; Guehl NJ; Verwer EE; Shoup TM; Yokell DL; Zubcevik N; Vasdev N; Zafonte RD; Johnson KA; El Fakhri G; Normandin MD
J Nucl Med; 2017 Mar; 58(3):484-491. PubMed ID: 27660144
[No Abstract] [Full Text] [Related]
12. Pilot Study: PARP1 Imaging in Advanced Prostate Cancer.
Dehdashti F; Reimers MA; Shoghi KI; Chen DL; Luo J; Rogers B; Pachynski RK; Sreekumar S; Weimholt C; Zhou D
Mol Imaging Biol; 2022 Dec; 24(6):853-861. PubMed ID: 35701722
[TBL] [Abstract][Full Text] [Related]
13. The evolving landscape of predictive biomarkers of response to PARP inhibitors.
Thomas A; Murai J; Pommier Y
J Clin Invest; 2018 May; 128(5):1727-1730. PubMed ID: 29664016
[TBL] [Abstract][Full Text] [Related]
14. PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies.
Michel LS; Dyroff S; Brooks FJ; Spayd KJ; Lim S; Engle JT; Phillips S; Tan B; Wang-Gillam A; Bognar C; Chu W; Zhou D; Mach RH; Laforest R; Chen DL
Radiology; 2017 Feb; 282(2):453-463. PubMed ID: 27841728
[TBL] [Abstract][Full Text] [Related]
15. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
[TBL] [Abstract][Full Text] [Related]
16. PARP-1 Expression Quantified by [
Sander Effron S; Makvandi M; Lin L; Xu K; Li S; Lee H; Hou C; Pryma DA; Koch C; Mach RH
Cancer Biother Radiopharm; 2017 Feb; 32(1):9-15. PubMed ID: 28118040
[TBL] [Abstract][Full Text] [Related]
17. Preclinical Evaluation and Quantification of
Khanapur S; van Waarde A; Dierckx RA; Elsinga PH; Koole MJ
J Nucl Med; 2017 Mar; 58(3):466-472. PubMed ID: 27789720
[TBL] [Abstract][Full Text] [Related]
18. [(18)F]Fallypride dopamine D2 receptor studies using delayed microPET scans and a modified Logan plot.
Tantawy MN; Jones CK; Baldwin RM; Ansari MS; Conn PJ; Kessler RM; Peterson TE
Nucl Med Biol; 2009 Nov; 36(8):931-40. PubMed ID: 19875049
[TBL] [Abstract][Full Text] [Related]
19. Whole tumor kinetics analysis of
McGowan DR; Skwarski M; Papiez BW; Macpherson RE; Gleeson FV; Schnabel JA; Higgins GS; Fenwick JD
EJNMMI Res; 2018 Aug; 8(1):73. PubMed ID: 30069753
[TBL] [Abstract][Full Text] [Related]
20. PET quantification of 18F-florbetaben binding to β-amyloid deposits in human brains.
Becker GA; Ichise M; Barthel H; Luthardt J; Patt M; Seese A; Schultze-Mosgau M; Rohde B; Gertz HJ; Reininger C; Sabri O
J Nucl Med; 2013 May; 54(5):723-31. PubMed ID: 23471310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
